Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats

Core Insights - Portela has become the first monoclonal antibody (mAb) therapy approved for a three-month dosing interval to alleviate pain associated with osteoarthritis (OA) in cats [1] Company Summary - The approval of Portela marks a significant advancement in veterinary medicine, particularly in the treatment of OA in felines [1] Industry Summary - This development highlights the growing trend in the animal health industry towards long-acting therapies, which can improve compliance and outcomes for pet owners and their animals [1]